Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
LNP023 for IgAN Patients
An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
Brief Description
The purpose of this study is to establish clinical proof-of-concept of effectiveness and to evaluate dose responses of the study drug in patients with IgAN.
Trial Physician / Study Coordinator
Novartis Pharmaceuticals
EmailSite Name
Novartis Investigative Site
Sponsor
Novartis Pharmaceuticals
Study Drug
LNP023
Estimated enrollment
48
Estimated end date
April, 2019
Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
LNP023 for IgAN Patients
An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
Brief Description
The purpose of this study is to establish clinical proof-of-concept of effectiveness and to evaluate dose responses of the study drug in patients with IgAN.
Trial is for people with
IgA Nephropathy
Study Goal
To determine if patients taking the study drug experience a change in their urine protein to creatinine concentration.
What is involved for the Patient?
Patients will be involved in the trial for about 3 months, and will need to do regular labwork.
About the drug or intervention
LNP023 is a new compound that is meant to stop inflammation in the body.